Pilot tolerability studies of hydroxychloroquine and colchicine in Alzheimer disease

被引：18

作者：

Aisen, PS ^{[1
]}

Marin, DB ^{[1
]}

Brickman, AM ^{[1
]}

Santoro, J ^{[1
]}

Fusco, M ^{[1
]}

机构：

[1] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA

来源：

ALZHEIMER DISEASE & ASSOCIATED DISORDERS | 2001年 / 15卷 / 02期

关键词：

inflammation; colchicine; hydroxychloroquine; clinical trial;

D O I：

10.1097/00002093-200104000-00009

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Anti-inflammatory drugs may be useful in the treatment of Alzheimer disease (AD). In preparation for therapeutic trials, we conducted pilot feasibility studies of hydroxychloroquine alone and in combination with colchicine in subjects with AD. A total of 20 subjects with probable AD were treated with hydroxychloroquine 200 mg twice daily for 11 weeks, or hydroxychloroquine 200 mg twice daily plus colchicine 0.6 mg twice daily for 12 weeks; subjects were monitored for adverse medical, cognitive, or behavioral effects. Neither regimen caused adverse effects on cognitive or behavioral assessment scores. There were no significant side effects in subjects receiving hydroxychloroquine alone; 2 subjects receiving the two drugs together experienced diarrhea. We conclude that these regimens of anti-inflammatory therapy are well tolerated in subjects with AD, indicating the feasibility of large-scale therapeutic trials of these agents.

引用

页码：96 / 101

页数：6

共 45 条

[1]

AISEN PS, 1994, AM J PSYCHIAT, V151, P1105

[2]

AISEN PS, 1996, ALZHEIMERS RES, V2, P153

[3]

Aisen PS, 1997, INT J GERIATR PSYCHO, V1, P2

[4] HYDROXYCHLOROQUINE SULFATE IN RHEUMATOID-ARTHRITIS - LONG-TERM RESPONSE RATE AND PREDICTIVE PARAMETERS [J].